Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252882 | 0.88 | RPS6KA3 (0.56) | HRH3CYP2D6RPS6KA3MAPKAPK2RPS6KA2 | |
| SCHEMBL38652638 | 0.82 | HRH3 (0.52) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL2980522 | 0.82 | HRH3 (0.52) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL38652559 | 0.82 | HRH3 (0.52) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL19187485 | 0.82 | HRH3 (0.52) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL1393632 | 0.80 | RPS6KA3 (0.53) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL30172384 | 0.80 | RPS6KA3 (0.53) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL29153647 | 0.78 | HRH3 (0.49) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL30104848 | 0.78 | HRH3 (0.49) | HRH3CYP2D6RPS6KA3MAPKAPK2PARP1 | |
| SCHEMBL4045284 | 0.78 | HRH3 (0.63) | HRH3CYP2D6PARP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254886-B1 | 3,4-DIHYDRO-2H-PYRAZINO[1,2-A]INDOL-1-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-05-25 | — | — | EP | disclosed |
| US-8513241-B2 | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-20 | — | — | US | disclosed |
| US-20120232085-A1 | 3,4-DIHYDRO-2H-PYRAZINO[1,2-A]INDOL-1-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-13 | — | — | US | disclosed |
| US-8207165-B2 | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-20110183971-A1 | 3,4-DIHYDRO-2H-PYRAZINO[1,2-A]INDOL-1-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-07-28 | — | — | US | disclosed |
| EP-2254886-A2 | 3,4-DIHYDRO-2H-PYRAZINOÝ1,2-A¨INDOL-1-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Nerviano Medical Sciences S.r.l. (IT) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009118411-A2 | 3,4-DIHYDRO-2H-PYRAZINO[1,2-A]INDOL-1-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183971-A1 | 3,4-DIHYDRO-2H-PYRAZINO[1,2-A]INDOL-1-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MAP3K1, PDPK1, MAP3K15 | HRH3 2046/4885CYP2D6 2082/4885RPS6KA3 208/4885 |
| US-20120232085-A1 | 3,4-DIHYDRO-2H-PYRAZINO[1,2-A]INDOL-1-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MAP3K1, PDPK1, MAP3K15 | HRH3 2046/4885CYP2D6 2082/4885RPS6KA3 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.